Raghida A. Bukhalid

Mersana Therapeutics (United States) — United States

Immunology and Microbiology · Life Sciences

17h-index1.8kcitations54works4.82yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

interferon and immune responses(22), HER2/EGFR in Cancer Research(16), Neuroblastoma Research and Treatments(16), Monoclonal and Polyclonal Antibodies Research(15), Ubiquitin and proteasome pathways(13)

Publications53 total

Supplementary Figure S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S7 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S1 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Data from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S4 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S2 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S6 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S5 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Figure S8 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
Supplementary Table S3 from XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
2025Open Access
XMT-2056, a HER2-Directed STING Agonist Antibody–Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells
Clinical Cancer Research·2025· 20 citedOpen Access
1053 XMT-2056, a HER2-targeted immunosynthen STING agonist antibody-drug conjugate, induces anti-tumor activity at low doses in preclinical models
Regular and Young Investigator Award Abstracts·2024· 1 citedOpen Access
Tumor cell-directed STING agonist antibody-drug conjugates induce type III interferons and anti-tumor innate immune responses
Nature Communications·2024· 55 citedOpen Access
Discovery and Optimization of a STING Agonist Platform for Application in Antibody Drug Conjugates
Journal of Medicinal Chemistry·2023· 45 citedOpen Access
Data from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
2023Open Access
Supplementary Table S1 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
2023Open Access
Supplementary Tables S2, S3, S4 from Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic
2023Open Access
page 1 of 3Next →

Frequent Co-authors

Kalli C. Catcott(22), Jeremy R. Duvall(22), Timothy B. Lowinger(22), Marc Damelin(22), Dorin Toader(21), Joshua D. Thomas(20), Travis Monnell(19), Pamela Shaw(18), Eugene Kelleher(18), Kelly L. Lancaster(17), Scott D. Collins(16), Timothy K. Eitas(16), Jeffrey Zurita(16), Ulrik B. Nielsen(14), Gege Tan(14), Naniye Malli Cetinbas(14), Jahna Soomer-James(14), Caitlin Routhier(14), Elizabeth Ditty(14), Nastaran Gerami-Moayed(13)